Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sezary Syndrome 1Sarcoma 1Rectal Neoplasms 1Paget Disease, Extramammary 1Mycosis Fungoides 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Eccrine Porocarcinoma 1Carcinoma, Signet Ring Cell 1Carcinoma, Merkel Cell 1Carcinoma, Basosquamous 1Carcinoma, Basal Cell 1Adenocarcinoma, Papillary 1

Interventions

Doxorubicin 5Specimen Handling 4Radiotherapy 4Magnetic Resonance Spectroscopy 3Biopsy 3pazopanib 2Radiation 2Nivolumab 2Ipilimumab 2Ifosfamide 2CTLA-4 Antigen 2talimogene laherparepvec 1saracatinib 1sapanisertib 1romidepsin 1peposertib 1pembrolizumab 1montanide ISA 51 1liposomal doxorubicin 1cixutumumab 1cabozantinib 1X-Rays 1Temozolomide 1Sorafenib 1Ritonavir 1Molecular Diagnostic Techniques 1Microarray Analysis 1MLN 8237 1Interleukin-2 1Indinavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Histiocytoma, Malignant Fibrous × talimogene laherparepvec × Clear all
NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡